Please upgrade your browser.
Cora Sternberg and colleagues 1 reported the efficacy of the multitargeted receptor tyrosine kinase inhibitor pazopanib for the treatment of metastatic renal cell carcinoma (RCC).
TopAbstracts in Renal Cancer are the abstracts most highly rated/most read by nearly 300,000 physicians who received a Doctor's Guide newsletter or visited a website Powered by Doctor's Guide in the past 14 days.
Research has shown that spontaneous regression of cancer occurs in cases of advanced melanoma, advanced kidney cancer and neuroblastoma (a childhood cancer of nerve tissue). Regression also occurs in colonic adenomas (precancerous growths of the colon) and in precancerous lesions of the cervix.
Wnt antagonist DKK1 acts as a tumor suppressor gene that induces apoptosis and inhibits proliferation in human renal cell carcinoma
The results suggest that DKK1 may not be involved in the betacatenin dependent pathway.
G-202 was shown to ablate tumors in animal models of breast cancer, prostate cancer and kidney cancer.
The AICR experts pointed out that those 72.5 million Americans face an increased risk for colorectal cancer, postmenopausal breast cancer, kidney cancer, esophageal cancer, endometrial cancer, pancreatic cancer and gallbladder cancer.
Sgt. George Alderete and Judith Buelow are just two of the survivors now being seen in survivorship clinics at MD Anderson, as the institution embraces another component of the cancer care cycle survivorship.
Since Obama signed healthcare reform into law, 22 states have filed lawsuits challenging the constitutionality of reform; at least 36 states have introduced initiatives repealing all or parts of healthcare reform. Aside from the obvious political ramifications, what does this obvious sign of discontent mean for our healthcare system moving forward?
The idea is to transplant cells to produce a new immune system that will attack the diseases. Earlier work around a decade ago failed to give lasting benefit, but new approaches aim for better results, said Dr. Michael Bishop of the National Cancer Institute.
Findings presented at this year's meeting will include new data on phase III kidney cancer drugs in development.
|Powered by NeonCRM|